A trial looking at gemcitabine and ganitumab for pancreatic cancer that has spread (GAMMA)

Cancer type:

Pancreatic cancer

Status:

Results

Phase:

Phase 3

This trial looked at the chemotherapy drug gemcitabine alongside a drug called ganitumab for pancreatic cancer that has spread to another part of the body.

More about this trial

Doctors usually treat pancreatic cancer that has spread with a chemotherapy drug called gemcitabine. But researchers are looking at ways to improve treatment for this group of people.

In this trial, they looked at a drug called ganitumab. It is a type of biological therapy called a monoclonal antibody. The researchers looked at different doses of ganitumab alongside gemcitabine, and compared these drug combinations with gemcitabine alone.

The aims of the trial were to

  • Find out if having ganitumab and gemcitabine helps people with advanced pancreatic cancer
  • Learn more about the side effects

Summary of results

The trial team found that having ganitumab alongside gemcitabine didn’t help people with pancreatic cancer that had spread.

This was a randomised trial. The people taking part were put into 1 of 3 groups at random. Neither they nor their doctor knew which group they were in. Researchers call this a double blind study. 800 people had treatment in this trial.

  • 322 had gemcitabine and a dummy drug (placebo)
  • 318 had gemcitabine and ganitumab
  • 160 had gemcitabine and a higher dose of ganitumab

Results of the trial were published in 2015 explaining that the trial was stopped early after a review by the committee that monitors the safety and design of the trial (the data monitoring committee). This was because early results suggested that it was very unlikely this trial would be able to show that ganitumab alongside gemcitabine helps people with advanced pancreatic cancer to live longer than gemcitabine alone.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Professor William Steward

Supported by

Amgen
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 8360

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Wendy took part in a new trial studying the possible side effect of hearing loss

A picture of Wendy

"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page